As anti-obesity medications like Ozempic and Wegovy become increasingly popular, American employees are making career choices based on access to them. A recent poll found that 1 in 5 Americans would be willing to switch jobs to get insurance coverage for these in-demand medications. But as the craze for GLP-1 drugs takes hold of the workforce, the question is—are we becoming a healthier society, or merely taking a medically approved shortcut?

In a world where job benefits such as remote work, unlimited time off, and child care allowances drive the benefits discussion, there's a new player in the mix: weight loss drugs. A 2024 survey by 9amHealth found that 67% of Americans would remain at a job they disliked if it included retaining access to drugs such as Ozempic and Wegovy. And if workplaces don't pay for them? 20% of respondents would actively seek another job.

This behavior is not without purpose. Out-of-pocket expenses for GLP-1 medications such as Ozempic can run over $1,000 monthly. Confronted with this expense, some users report skimping on necessities such as food and entertainment in order to pay for their monthly supply. Coverage under employer-sponsored insurance, thus, becomes not only a benefit—but a necessity.

What is the Frenzy of GLP-1 Drugs?

Contrary to older weight loss drugs that normally achieve a 5% drop in body weight, newer GLP-1 medications provide up to 20% weight loss or more. Their impact has been so significant that Science identified GLP-1 medications as the 2023 "Breakthrough of the Year." The medications act by emulating a hormone that controls blood glucose and hunger, leading to both enhanced metabolic function and reduced hunger.

Initially approved for type 2 diabetes, Ozempic and other medications such as Mounjaro have been used extensively off-label for weight loss, driving stratospheric demand. In February 2023 alone, over 373,000 prescriptions for Ozempic were filled—a 111% increase from the year before.

Ozempic: High Demand, Higher Costs, and Potential Misuse

But with increasing demand comes increasing expense. Ozempic and Mounjaro were among 800 drugs that experienced a median list price increase of 4.5% this year, the Wall Street Journal reported. Some large institutions, such as Ascension Health and the University of Texas System, have even withdrawn coverage in light of skyrocketing prices—reporting a 233% increase in expenditures related to them.

According to the World Health Organization, over 80% of people with type 2 diabetes are overweight or obese. Chronic inflammation caused by excess fat, especially visceral fat, disrupts how insulin functions. Additionally, high levels of circulating fatty acids can impair insulin sensitivity.

Dr. Arush Sabharwal, Bariatric & Metabolic Surgeon explains, "This is where GLP-1 receptor agonists like Ozempic (semaglutide) come into the picture. Originally approved for type 2 diabetes, Ozempic also promotes weight loss by suppressing appetite and slowing gastric emptying. Clinical trials have shown significant weight reduction and improved blood sugar control in patients using it."

"Though Ozempic is not a magic solution, still it denotes a powerful association between the role of weight management and type 2 diabetes. For those who are overweight, lifestyle modifications are important, after seeking professional advice from a weight loss expert like a doctor/bariatric surgeon/certified nutritionist."

There's also an increasing worry about the abuse and stigma surrounding these medications. Although Ozempic is now a cultural buzzword and an alleged "magic bullet" for rapid weight loss, physicians warn that it's not a sustainable solution in and of itself. "Without robust support for behavior change, weight loss is generally short-term and tends to be followed by weight regain," experts in endocrinology and metabolic care stated.

In fact, 38% of respondents to the 9amHealth poll confessed to exploring black market sources prior to settling on FDA-accepted treatments—courageous behavior that reveals the desperation and lack of education about obesity management.

Why Obesity is an Expensive, Long-Term Health Problem Employers Can't Dismiss?

Over 40% of American adults qualify for the CDC's definition of obesity, a BMI of 30 or more. The disorder is a significant cause of comorbidities such as type 2 diabetes, hypertension, and cardiovascular disease—a combination frequently called "cardiodiabesity." Alone, obesity costs the U.S. healthcare system $173 billion per year and accounts for $6.38 billion in lost productivity in the workplace.

With these daunting numbers, employers are finally realizing that managing obesity up front may be cheaper in the long term. In 2023, only 25% of employers were covering GLP-1s, but this might increase to 43% in 2024, says health consulting company Accolade.

But selling prescription medications without complementing them with health support is a lost chance. Specialists recommend a combined approach—of accessible pharmaceuticals along with dietary advice, exercise routine, psychiatric help, and regular medical follow-up.

Medical Experts Call for Balanced Approach

While the temptation of GLP-1 medications can be tempting, specialists advise against its use as a single solution. Pills can trigger weight loss, but long-term health is derived from behavioral modification. Fitch and others suggest addressing obesity as any chronic illness, with long-term, multidimensional management.

Dr. Arush emphasises, "There is a strong connecting link between type 2 diabetes and obesity. When there is excess deposition of abdominal fat, it makes the body insulin resistant. This is a condition wherein the body finds it hard to respond to insulin hormone and this in turn, surges the blood sugar levels. Ultimately this makes the body predisposed to type 2 diabetes."

Employers who are seriously interested in tackling obesity in the workplace need to look beyond providing coverage. They must make available comprehensive health packages that consist of individualized interventions, ongoing tracking, and lifestyle change support systems for enduring change.

For the time being, it appears GLP-1 medications are not only changing waistlines, but also workplaces. Workers are willing to make drastic life adjustments—including job-hopping—for access to these drugs. Whether this is a significant shift in corporate healthcare priorities or a troubling shortcut remains to be determined.

One thing is certain, the workplace is emerging as a central front in the battle against obesity. And as the stakes grow higher, so does the onus on employers to provide intelligent, sustainable, and equitable solutions for the long-term health of their employees.

Dr. Arush Sabharwal is a Bariatric & Metabolic Surgeon at SCOD Clinic in India

Chai and pakoras are practically non-negotiable once the rains set in. For a large number of Indians, though, monsoon comes with something less welcome: a blocked nose, itchy eyes, and a "cold" that just won't quit.

Most people write this off as a seasonal cold. It's often not. A large share of the patients I see in July aren't fighting a fresh infection. They're dealing with allergic rhinitis that's been present for months at a manageable level, and monsoon has simply pushed it past a threshold they can no longer ignore.

A Bigger Problem Than It Looks

The scale of this is easy to underestimate. A national study under the Global Asthma Network, which surveyed more than 1.27 lakh children, adolescents, and adults across India, found that close to a quarter of Indian adolescents aged 13 to 14 live with allergic rhinitis. Roughly one in ten adults does too.

Other Indian research puts the overall incidence of allergic rhinitis anywhere between 20 and 30 percent of the population. This isn't a niche complaint. It's one of the more common chronic conditions walking through general practice doors, most of which are simply unnamed.

Mostly Undiagnosed, Rarely Treated Right

The same national study found something more concerning: nearly three out of four people who met the clinical criteria for allergic rhinitis had never actually been diagnosed with it. Many had lived with recurring congestion, sneezing, and disturbed sleep for years without anyone connecting the dots.

A separate survey of over 1,600 physicians across India found that while a large share see allergic rhinitis routinely in practice, more than half had never used immunotherapy, one of the few treatments that changes the course of the disease rather than just quieting it temporarily.

Why Monsoon Makes It Worse

Indian allergen-testing data show a clear rotation of triggers through the year: dust mites dominate winter, pollens dominate summer, and fungal and insect allergens rise sharply once the rains set in.

The reason is straightforward. Once relative humidity in a city climbs past 70 percent, which happens routinely through the monsoon, fungal spores and dust mites both multiply fast. Waterlogging pushes fungal spore counts up further. A damp curtain or a mattress that never quite dries between showers becomes a long-term allergen source that outlasts any single rainy day.

It Rarely Comes Alone

Allergic skin and eye conditions tend to flare with the same seasonal humidity and allergen load as allergic rhinitis, and in practice, they rarely show up in isolation. A patient with monsoon-triggered nasal symptoms is worth a closer look for coexisting asthma, eczema, or conjunctivitis, simply because in the Indian patient population, these conditions travel together more often than not.

What Actually Helps

For anyone with a known allergic condition, a few habits make a real difference once the rains arrive:

• Start early. Begin or review your antihistamine or inhaled treatment before the monsoon sets in, not after symptoms flare. Allergic inflammation is far easier to control early than to bring down once it's escalated.
• Keep the fabric genuinely dry. Bedding, curtains, and upholstery that stay even slightly damp become breeding grounds for the mold and dust mites driving most flares. Check for indoor allergens rather than just blaming obvious outdoor ones.
• Ventilate or dehumidify. Especially in bedrooms, where hours of overnight exposure do the most damage.
• Keep rescue medication accessible through the season, not just on bad days.
• Don't wait out a flare that lasts beyond a week. That's usually the point where a proper allergy workup is overdue.
• If it happens every single monsoon, that pattern itself is a diagnosis worth acting on, not just enduring.

Monsoon doesn't create new allergy patients. It reveals how well the existing ones are actually being looked after.

“Let knowledge be your shield against the changing seasons."

Even a mild case of COVID-19 may trigger long-lasting eye problems, with new research revealing that persistent inflammation and nerve damage could be responsible for symptoms that standard eye tests often fail to detect.

The study, led by researchers at Linköping University in Sweden and published in Nature Communications, sheds light on why some COVID-19 survivors continue to experience debilitating vision issues months or even years after infection.

The research began after people who had recovered from mild COVID-19 sought medical help for persistent eye complaints. Many reported:

• Severe eye pain
• Light sensitivity (photophobia)
• Difficulty reading and focusing
• Extreme eye fatigue

Many participants said the condition significantly disrupted their daily lives, preventing them from working or continuing their education.

What the Study Found

Also read: Experts Say US Cyclospora Parasite Outbreak Is Unusual: How To Clean Fresh Produce

Researchers evaluated 100 people who developed eye problems after mild COVID-19 but had never been hospitalized. Their symptoms had persisted anywhere from three months to three years.

The findings were compared with those of 32 people who had recovered from mild COVID-19 without developing eye symptoms.

Using advanced imaging and laboratory techniques, researchers identified several abnormalities that conventional eye exams failed to detect.

Persistent Inflammation and Nerve Damage

The study found evidence of:

• Long-term inflammation in the eyes
• Damage to nerves controlling multiple eye functions
• Abnormal immune activity involving T cells
• Changes in proteins found in tear fluid

Lead author Petros Moustardas, senior research associate at Linköping University, said the findings indicate that COVID-19 may trigger a severe immune reaction in the eyes, resulting in chronic inflammation and nerve dysfunction.

Why Light Sensitivity Happens

Read More: Obesity-Driven CKM Syndrome A Growing Public Health Threat, Warns American Heart Association

One of the most common complaints among participants was extreme sensitivity to light. Researchers found that their pupils were allowing too much light into the eyes because of impaired nerve control.

This abnormal pupil function was also associated with:

• Headaches
• Difficulty reading
• Trouble maintaining focus

An Unusual Eye Movement Disorder

The study also identified impaired coordination between the two eyes.

Some participants developed adult-onset strabismus—commonly known as crossed eyes—a condition that is rare in adults.

Researchers believe this occurred because COVID-19 affected the nerves responsible for controlling eye muscles.

A New Way to Diagnose COVID-Related Eye Problems

Because routine eye tests often miss these abnormalities, the research team developed two diagnostic models.

The first relies on specialized ophthalmic tests available at advanced eye clinics, while the second combines these examinations with tear fluid protein analysis to improve diagnostic accuracy.

Researchers hope these models will help doctors recognize COVID-related eye syndrome earlier and pave the way for future treatments.

"We found that the problems experienced by those affected were not detectable by standard tests. We had to perform specialised examinations to detect deviations. The puzzle pieces then fell into place, and we found explanations for the symptoms," said Neil Lagali, professor of experimental ophthalmology at Linköping University.

He added that while the findings provide important clues about how COVID-19 affects the eyes, more research is needed to develop effective treatments for those living with persistent vision problems.

Plant-based Vitamin D3 is often marketed as a healthier or superior alternative to traditional supplements, but doctors say that's not necessarily the case.

According to Dr. Murtaza S. Bagwala, Head of Emergency Medical Services at Saifee Hospital in Mumbai, existing research shows that plant-based Vitamin D3 is just as effective as conventional Vitamin D3 in increasing the body's vitamin D levels.

"Current evidence suggests that plant-based Vitamin D3 performs similarly to conventional Vitamin D3 supplements. For people who prefer vegan or plant-based products, it is a suitable alternative," he told HealthandMe.

Echoing this view, Dr. Sudhir Kumar, Neurologist at Apollo Hospitals in Hyderabad, said that plant-derived Vitamin D3—usually obtained from lichen, algae, or modern fermentation methods—provides an animal-free option without sacrificing effectiveness.

In a post on X, he noted that while plant-based Vitamin D3 is welcome news for vegans and those seeking cruelty-free supplements, both forms work equally well. He added that there is no medical need for people to switch if they are already taking conventional Vitamin D3 supplements.

Also Read: Chandipura Virus Claims 3 Children In Gujarat, Rajasthan: Why Kids Are At Risk Of This Rare Brain Infection

India has approved its first plant-based Vitamin D3 (cholecalciferol) ingredient, a move that could expand options for food fortification and dietary supplements while addressing the country's widespread Vitamin D deficiency.

The Food Safety and Standards Authority of India (FSSAI) has cleared VITADEE Green, developed by Fermenta Biotech, for use in health supplements, nutraceuticals and food products.

The company stated that the ingredient is produced using an India-patented process and offers a sustainable, scalable and vegetarian-friendly source of Vitamin D3.

The approval allows Indian manufacturers to incorporate the ingredient into fortified foods, beverages and dietary supplements.

It is particularly significant for vegetarians and vegans, who have traditionally had limited access to Vitamin D3 because most supplements are derived from lanolin, a by-product of sheep's wool.

The approval also supports India's broader efforts to improve nutrition through food fortification, an area where experts say Vitamin D remains a major gap.

What Is Vitamin D3?

Vitamin D3, often called the "sunshine vitamin," is produced by the body when the skin is exposed to sunlight.

It helps the body absorb calcium, maintain healthy bones and teeth, and lowers the risk of fractures. In children, severe deficiency can lead to rickets, while in adults it increases the risk of osteoporosis, muscle weakness, and falls.

Beyond bone health, Vitamin D3 also supports immune function. Research suggests low Vitamin D levels may be associated with increased susceptibility to infections and higher levels of inflammation.

Who Should Take Vitamin D3 Supplements?

The experts said the key question is whether supplementation is needed, not whether the source is plant- or animal-derived.

"The source matters mainly for ethical, dietary or personal preference—not for efficacy," Dr. Sudhir said.

Dr. Bagwala cautioned against taking high-dose Vitamin D without medical advice, as excessive intake can raise calcium levels and increase the risk of kidney stones and other complications.